Investors Warned of Potential Securities Fraud in GeneDx Holdings Class Action

GeneDx Holdings Faces Class Action Lawsuit Over Securities Fraud

Investors in GeneDx Holdings Corp. are being urged to take action as the company faces a class action lawsuit stemming from significant misrepresentations related to its acquisition performance. The lawsuit, pending in the United States District Court for the District of Connecticut, has been filed by Kahn Swick & Foti, LLC (KSF) on behalf of shareholders who suffered substantial losses. KSF attorney Charles C. Foti, Jr., a former Attorney General of Louisiana, is spearheading this initiative, advising investors of their rights to participate in the lawsuit.

Important Dates and Information

The critical timeline for affected investors is as follows: those who purchased or otherwise acquired shares of GeneDx between April 16, 2025, and May 4, 2026, can file lead plaintiff applications until August 3, 2026. This period, referred to as the 'Class Period,' encompasses the timeframe in which the alleged fraudulent activities occurred. Investors who wish to discuss their legal options or potential claims can reach out to Kahn Swick directly via several methods, including toll-free calls and emails.

Background on the Allegations

The core of the class action lawsuit stems from allegations that GeneDx and several of its executives failed to disclose crucial information which would have impacted investor decisions. During the Class Period, the company reported dismal financial results for the first quarter of the fiscal year 2026. Specifically, it noted a shocking decline in its adjusted gross margin from 74% to 69% and failed to meet its revenue estimates for its exome and genome products. Furthermore, the company significantly reduced its revenue guidance for the entire year, predicting earnings between $475 million and $490 million, substantially lower than the previous estimates of $540 million to $550 million.

Additionally, GeneDx disclosed a significant impairment loss of $31.2 million associated with its acquisition of Fabric Genomics, a company it had once positioned as a catalyst for growth due to its innovative AI-driven genomic interpretation capabilities. This alarming news resulted in a catastrophic drop in GeneDx’s stock price, falling by $33.42 per share—or roughly 49.2%. Such a dramatic decline illustrates the potential impact of the alleged misrepresentations on shareholders.

Legal Representation and Next Steps

Investors affected by this situation are encouraged to engage with KSF, which has established itself as a prominent player in securities litigation. The firm specializes in recovering losses incurred due to corporate fraud, leveraging its extensive experience and successful track record. KSF has reported its strategies and experiences in legal recoveries and is committed to representing both institutional and retail clients.

To proceed as a lead plaintiff in this significant class action, shareholders must formally petition the court by the deadline of August 3, 2026. As the legal proceedings unfold, shareholders are advised to stay informed and seek guidance on how these actions may influence their rights and potential recoveries.

Conclusion

The GeneDx class action lawsuit underscores the vital need for transparency and integrity in corporate reporting. Affected investors should take immediate action to protect their rights, considering the precedent that wrongful financial disclosures can set in the world of public companies. Collaborative action has the potential to hold corporations accountable and restore investor trust. For more comprehensive details on the case and how to assert your rights, consider contacting Kahn Swick & Foti, LLC or visiting their website for additional resources.

Further updates regarding this case will be provided as more information becomes available, ensuring involved parties can stay engaged through the ongoing legal process.